Christopher Christoforou - Nevro Corp Vice President - Research and Development
| NVRO Stock | USD 10.58 0.84 7.36% |
President
Mr. Christopher Christoforou is Vice President Research and Development of the Company. since July 2016. From December 2014 to July 2016, Mr. Christoforou served as Vice President, Quality Engineering at Thoratec Corporationrationration, a medical device company where he oversaw the operational, design and supplier quality engineering functions. From October 1999 to December 2014, Mr. Christoforou served in several leadership positions of increasing levels of responsibility at Thoratec Corporationrationration. From August 1993 to February 1999, Mr. Christoforou served as a Manager of Engineering and various Engineering positions for United States Surgical Corporationrationration, a producer of tools for use in surgery since 2020.
| Age | 50 |
| Tenure | 4 years |
| Address | 1800 Bridge Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 251 0005 |
| Web | https://nevro.com |
Nevro Corp Management Efficiency
The company has return on total asset (ROA) of (0.1003) % which means that it has lost $0.1003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2989) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of May 2024, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 1st of May 2024, Intangible Assets is likely to grow to about 33 M, while Total Assets are likely to drop about 461.8 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Kathryn Torres | HCA Holdings | 57 | |
| Robert Oliva | Novo Integrated Sciences | 60 | |
| Sandra Morgan | HCA Holdings | 57 | |
| William Rutherford | HCA Holdings | 60 | |
| Charles Hall | HCA Holdings | 71 | |
| Jon Foster | HCA Holdings | 62 | |
| Ravi Chari | HCA Holdings | 51 | |
| Alan Yuspeh | HCA Holdings | 67 | |
| Troy Villarreal | HCA Holdings | N/A | |
| Phillip Billington | HCA Holdings | 56 | |
| Robert Waterman | HCA Holdings | 66 | |
| John Hollinsworth | Acadia Healthcare | 60 | |
| Christopher David | Novo Integrated Sciences | 65 | |
| Dan Miller | HCA Holdings | N/A | |
| Victor Campbell | HCA Holdings | 71 | |
| Bruce Moore | HCA Holdings | 52 | |
| Joseph Sowell | HCA Holdings | 64 | |
| Jana Davis | HCA Holdings | 57 | |
| John Steele | HCA Holdings | 62 | |
| Donald Stinnett | HCA Holdings | 58 | |
| Greg Lowe | HCA Holdings | N/A | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.1 |
Nevro Corp Leadership Team
Elected by the shareholders, the Nevro Corp's board of directors comprises two types of representatives: Nevro Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nevro. The board's role is to monitor Nevro Corp's management team and ensure that shareholders' interests are well served. Nevro Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nevro Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ali Behbahani, Director | ||
| Michael Enxing, VP of Sales and Marketing | ||
| Julie Dewey, Vice President - Investor Relations and Corporate Communications | ||
| Tamara Rook, Vice President - Health Economics & Reimbursement | ||
| Elizabeth Weatherman, Independent Director | ||
| Brad Vale, Independent Director | ||
| Donald Middlebrook, Vice President - Clinical, Regulatory and Quality | ||
| Douglas Alleavitch, Vice President - Quality | ||
| Christopher Christoforou, Vice President - Research and Development | ||
| Kevin OBoyle, Independent Director | ||
| Meredith Vornholt, Vice Marketing | ||
| Shawn McCormick, Independent Director | ||
| Rami Elghandour, President | ||
| David Caraway, Chief Medical Officer | ||
| Christofer Christoforou, Senior Operations | ||
| DKeith Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Patrick Schmitz, Vice President - Operations | ||
| Richard Carter, Chief Officer | ||
| Sridhar Kosaraju, Director | ||
| Frank Fischer, Independent Director | ||
| Michael DeMane, Lead Independent Director | ||
| Lisa Earnhardt, Director | ||
| Kevin Thornal, CEO President | ||
| Roderick MacLeod, Chief Financial Officer | ||
| Shana MBA, Senior Officer | ||
| Andre Walker, Senior Vice President Research & Development | ||
| Michael Carter, Vice President - Global Sales | ||
| D Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Wilfred Jaeger, Director | ||
| Susan Siegel, Independent Director | ||
| Andrew Galligan, CFO and VP of Fin. | ||
| Karen Prange, Independent Director | ||
| Bradford Gliner, Vice President - Clinical & Regulatory | ||
| Kashif Rashid, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
| Geeta Kaveti, VP Officer | ||
| Niamh Pellegrini, Chief Commercial Officer | ||
| Lori Ciano, Chief Human Resource Officer | ||
| David MD, Senior Officer | ||
| Doug Alleavitch, VP of Quality and Operations | ||
| Jon Shear, Senior Development |
Nevro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nevro Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 314.77 M | ||||
| Shares Outstanding | 36.68 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 96.74 % | ||||
| Number Of Shares Shorted | 4.17 M | ||||
| Price To Earning | (63.38) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Nevro Stock analysis
When running Nevro Corp's price analysis, check to measure Nevro Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nevro Corp is operating at the current time. Most of Nevro Corp's value examination focuses on studying past and present price action to predict the probability of Nevro Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nevro Corp's price. Additionally, you may evaluate how the addition of Nevro Corp to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Nevro Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.56) | Revenue Per Share 11.816 | Quarterly Revenue Growth 0.02 | Return On Assets (0.10) | Return On Equity (0.30) |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.